Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | CCR6 | P51684 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL524167 | 0.86 | TRPV4 (0.52) | KDM4EALDH1A1L3MBTL1KIF11CCR6 | |
| SCHEMBL29480819 | 0.86 | TRPV4 (0.52) | KDM4EALDH1A1L3MBTL1KIF11CCR6 | |
| SCHEMBL29858989 | 0.82 | ALDH1A1 (0.43) | KDM4EALDH1A1L3MBTL1KIF11CCR6 | |
| SCHEMBL1420598 | 0.82 | KDM4E (0.40) | KDM4EALDH1A1L3MBTL1KIF11CCR6 | |
| SCHEMBL8946680 | 0.82 | KIF11 (0.41) | KDM4EALDH1A1L3MBTL1KIF11CCR6 | |
| SCHEMBL18397439 | 0.82 | ALDH1A1 (0.43) | KDM4EALDH1A1L3MBTL1KIF11CCR6 | |
| SCHEMBL12464107 | 0.79 | KDM4E (0.38) | KDM4EALDH1A1L3MBTL1KIF11CCR6 | |
| SCHEMBL18443352 | 0.78 | HSD11B1 (0.38) | KDM4EALDH1A1L3MBTL1KIF11CCR6 | |
| SCHEMBL18443350 | 0.78 | KDM4E (0.37) | KDM4EALDH1A1L3MBTL1KIF11CCR6 | |
| SCHEMBL1243269 | 0.78 | ALDH1A1 (0.46) | KDM4EALDH1A1L3MBTL1KIF11CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590084-B2 | Oxadiazole HDAC6 inhibitors and uses thereof | EIKONIZO THERAPEUTICS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260055090-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2026-02-26 | — | — | US | disclosed |
| US-20250250263-A1 | INHIBITING HISTONE DEACETYLASE 6 (HDAC6) | EIKONIZO THERAPEUTICS, INC. (US) | 2025-08-07 | — | — | US | disclosed |
| CN-119451678-A | Inhibition of histone deacetylase 6 (HDAC 6) | 艾科尼佐治疗股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-4504191-A1 | INHIBITING HISTONE DEACETYLASE 6 (HDAC6) | Eikonizo Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023196605-A1 | INHIBITING HISTONE DEACETYLASE 6 (HDAC6) | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023196601-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023196605-A1 | INHIBITING HISTONE DEACETYLASE 6 (HDAC6) | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-1998016526-A1 | TETRAHYDRO-6H-PYRAZINO[1,2-B]ISOQUINOLINE 1,4-DIONES AS APOPROTEIN B-100 INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC11 | KDM4E 2674/4885ALDH1A1 755/4885L3MBTL1 2746/4885 |
| US-12590084-B2 | Oxadiazole HDAC6 inhibitors and uses thereof | HDAC6, HDAC1, HDAC9 | KDM4E 1491/4885ALDH1A1 2216/4885L3MBTL1 2432/4885 |
| US-20260055090-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, CTTN | KDM4E 3413/4885ALDH1A1 2666/4885L3MBTL1 3673/4885 |
| US-20250250263-A1 | INHIBITING HISTONE DEACETYLASE 6 (HDAC6) | HDAC6, HDAC1, HDAC9 | KDM4E 1593/4885ALDH1A1 1703/4885L3MBTL1 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.